Imazamethabenz inhibits human breast cancer cell proliferation, migration and invasion via combination with Pin1

Liu,Chen; Mu,Chaoyu; Li,Zeng; Xu,Liang

doi:10.3892/mmr.2017.6399

Imazamethabenz inhibits human breast cancer cell proliferation, migration and invasion via combination with Pin1

Authors:
- Chen Liu
- Chaoyu Mu
- Zeng Li
- Liang Xu
View Affiliations

Affiliations: College of Pharmacy, Anhui Medical University, Hefei, Anhui 230032, P.R. China
Published online on: March 28, 2017 https://doi.org/10.3892/mmr.2017.6399
Pages: 3210-3214

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Overexpression of peptidyl-prolyl cis/trans isomerase, NIMA interacting‑1 (Pin1) is a significant marker of the occurrence and development of tumors. In the present study, the imidazoline ketone herbicide imazamethabenz was investigated as a potential antitumor drug by inhibiting Pin1. Molecular docking and enzyme activity tests verified, for the first time, that the imidazoline ketone compound imazamethabenz effectively inhibited Pin1 in vitro. MTT assays, western blotting, wound healing assay and Matrigel invasion assays revealed that imazamethabenz induced apoptosis and inhibited migration and invasion of the breast cancer cell line MCF‑7, which overexpresses Pin1, by inhibiting the Pin1‑mediated signaling pathway involving vascular endothelial growth factor and matrix metalloproteinase 9. These findings indicated that imazamethabenz offers potential applications for the treatment of tumors as a Pin1 inhibitor.

View Figures

View References

1	Lu KP, Hanes SD and Hunter T: A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature. 380:544–547. 1996. View Article : Google Scholar : PubMed/NCBI
2	Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP and Wang DG: Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol. 164:1727–1737. 2004. View Article : Google Scholar : PubMed/NCBI
3	Yeh ES and Means AR: PIN1, the cell cycle and cancer. Nat Rev Cancer. 7:381–388. 2007. View Article : Google Scholar : PubMed/NCBI
4	Sorrentino G, Comel A, Mantovani F and Del Sal G: Regulation of mitochondrial apoptosis by Pin1 in cancer and neurodegeneration. Mitochondrion. 19:88–96. 2014. View Article : Google Scholar : PubMed/NCBI
5	Lin CH, Li HY, Lee YC, Calkins MJ, Lee KH, Yang CN and Lu PJ: Landscape of Pin1 in the cell cycle. Exp Biol Med (Maywood). 240:403–408. 2015. View Article : Google Scholar : PubMed/NCBI
6	Keune WJ, Jones DR and Divecha N: PtdIns5P and Pin1 in oxidative stress signaling. Adv Biol Regul. 53:179–189. 2013. View Article : Google Scholar : PubMed/NCBI
7	Marsolier J and Weitzman JB: Pin1: A multi-talented peptidyl prolyl cis-trans isomerase and a promising therapeutic target for human cancers. Med Sci (Paris). 30:772–778. 2014.(In French). View Article : Google Scholar : PubMed/NCBI
8	Yoon HE, Kim SA, Choi HS, Ahn MY, Yoon JH and Ahn SG: Inhibition of Plk1 and Pin1 by 5′-nitro-indirubinoxime suppresses human lung cancer cells. Cancer Lett. 316:97–104. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhu L, Jin J, Liu C, Zhang C, Sun Y, Guo Y, Fu D, Chen X and Xu B: Synthesis and biological evaluation of novel quinazoline-derived human Pin1 inhibitors. Bioorg Med Chem. 19:2797–2807. 2011. View Article : Google Scholar : PubMed/NCBI
10	Nakagawa H, Seike S, Sugimoto M, Ieda N, Kawaguchi M, Suzuki T and Miyata N: Peptidyl prolyl isomerase Pin1-inhibitory activity of D-glutamic and D-aspartic acid derivatives bearing a cyclic aliphatic amine moiety. Bioorg Med Chem Lett. 25:5619–5624. 2015. View Article : Google Scholar : PubMed/NCBI
11	Newsome WH and Collins PG: Determination of imazamethabenz in cereal grain by enzyme-linked immunosorbent assay. Bull Environ Contam Toxicol. 47:211–216. 1991. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Daum S, Wildemann D, Zhou XZ, Verdecia MA, Bowman ME, Lücke C, Hunter T, Lu KP, Fischer G and Noel JP: Structural basis for high-affinity peptide inhibition of human Pin1. ACS Chem Biol. 2:320–328. 2007. View Article : Google Scholar : PubMed/NCBI
13	Dong L, Marakovits J, Hou X, Guo C, Greasley S, Dagostino E, Ferre R, Johnson MC, Kraynov E, Thomson J, et al: Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 20:2210–2214. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kofron JL, Kuzmic P, Kishore V, Colón-Bonilla E and Rich DH: Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry. 30:6127–6134. 1991. View Article : Google Scholar : PubMed/NCBI
15	Yuan SS, Hou MF, Hsieh YC, Huang CY, Lee YC, Chen YJ and Lo S: Role of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer. J Natl Cancer Inst. 104:1485–1502. 2012. View Article : Google Scholar : PubMed/NCBI
16	Liu C, Jin J, Chen L, Zhou J, Chen X, Fu D, Song H and Xu B: Synthesis and biological evaluation of novel human Pin1 inhibitors with benzophenone skeleton. Bioorg Med Chem. 20:2992–2999. 2012. View Article : Google Scholar : PubMed/NCBI
17	Min SH, Zhou XZ and Lu KP: The role of Pin1 in the development and treatment of cancer. Arch Pharm Res. 39:1609–1620. 2016. View Article : Google Scholar : PubMed/NCBI
18	Lin CH, Li HY, Lee YC, Calkins MJ, Lee KH, Yang CN and Lu PJ: Landscape of Pin1in the cell cycle. Exp Biol Med (Maywood). 240:403–408. 2015. View Article : Google Scholar : PubMed/NCBI
19	Litchfield DW, Shilton BH, Brandl CJ and Gyenis L: Pin1: Intimate involvement with the regulatory protein kinase networks in the global phosphorylation landscape. Biochim Biophys Acta. 1850:2077–2086. 2015. View Article : Google Scholar : PubMed/NCBI
20	Kim MR, Choi HS, Heo TH, Hwang SW and Kang KW: Induction of vascular endothelial growth factor by peptidyl-prolyl isomerase Pin1 in breast cancer cells. Biochem Biophys Res Commun. 369:547–553. 2008. View Article : Google Scholar : PubMed/NCBI